Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Fourth Quarter and Year End 2011 Financial Results
01 févr. 2012 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals Motion for Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. Stayed
26 janv. 2012 13h15 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Jan. 26, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta to Host Investor Conference Call on December 23, 2011 to Discuss Follow-On Biologics Collaboration With Baxter
22 déc. 2011 16h19 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Dec. 22, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Acquires Assets From Virdante Pharmaceuticals
05 déc. 2011 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Dec. 5, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
TIME CHANGE: Momenta Pharmaceuticals to Present at the 2011 Deutsche Bank BioFEST
01 déc. 2011 14h15 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Dec. 1, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals to Present at the 2011 Deutsche Bank BioFEST
28 nov. 2011 17h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 28, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports $1.18 Earnings per Share for the Third Quarter of 2011
07 nov. 2011 08h51 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Nov. 7, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Obtains Preliminary Injunction Against Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd.
28 oct. 2011 16h47 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Oct. 28, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces That Launch of Authorized Generic Lovenox(R) Triggers Change in Collaboration Terms
24 oct. 2011 17h13 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Oct. 24, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2011 Financial Results
24 oct. 2011 10h45 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Oct. 24, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...